Risk Factors for Post-ERCP Pancreatitis in High-Risk Patients Receiving Post-procedure Rectal Indomethacin

被引:12
|
作者
Kang, Xiaoyu [1 ]
Zheng, Liyue [1 ]
Zeng, Wei [2 ,3 ]
Yang, Shengye [1 ]
Sun, Hao [4 ]
Zhang, Rongchun [1 ]
Wang, Xiangping [1 ]
Wang, Biaoluo [1 ]
Tao, Qin [1 ]
Yao, Shaowei [1 ]
Chen, Jie [1 ]
Pan, Yanglin [1 ]
Guo, Xuegang [1 ]
机构
[1] Fourth Mil Med Univ, Xijing Hosp Digest Dis, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China
[2] Chinese PLA 174 Hosp, Dept Gastroenterol, Xiamen, Fujian, Peoples R China
[3] Xiamen Univ, Chenggong Hosp, Dept Gastroenterol, Xiamen, Fujian, Peoples R China
[4] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
ERCP; Post-ERCP pancreatitis; Indomethacin; Risk factors; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; STENT PLACEMENT; CANNULATION; COMPLICATIONS; METAANALYSIS; PREVENTION; REDUCE; MANAGEMENT; EFFICACY;
D O I
10.1007/s11605-018-3864-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Post-ERCP pancreatitis (PEP) is the most common adverse event of ERCP. Rectal indomethacin has been widely administered to decrease the incidence of PEP in high-risk patients. However, it cannot completely prevent the occurrence of PEP. The purpose of the study was to evaluate the risk factors for PEP in high-risk patients receiving post-ERCP indomethacin. Methods From June 2012 to July 2015, patients undergoing ERCP and at high risk for PEP in three tertiary hospitals in China were enrolled. All patients received indomethacin after the procedure. Patient-related and procedure-related risk factors for PEP were collected. Logistic regression analysis was used to investigate the risk factors. Results Seven hundred ninety patients at high risk for PEP received post-ERCP indomethacin. The incidence of overall PEP and moderate-to-severe PEP was 8.0 and 1.5%, respectively. In multivariate analysis, suspected sphincter of Oddi dysfunction (SOD) (OR 2.73; 95%CI 1.38-5.43; p=0.004), the presence of hilar obstruction (OR 4.53; 95%CI 1.60-12.81; p=0.004), number of cannulation attempts 13 (OR 2.00; 95%CI 1.07-3.77; p=0.030), inadvertent pancreatic duct (PD) cannulation 1 (OR 2.26; 95%CI 1.04-4.90; p=0.040), and pancreatic contrast injections 1 (OR 2.30; 95%CI 1.02-5.23; p=0.046) were high risk factors for overall PEP. For moderate-to-severe PEP, suspected SOD (OR 4.67; 1.19-18.35; p=0.027), the presence of hilar obstruction (OR 7.95; 1.39-44.97; p=0.010), and more cannulation attempts (OR 3.71; 1.09-12.65; p=0.036) were three independent risk factors. Conclusions A substantial number of high-risk patients had PEP even receiving post-ERCP rectal indomethacin. The independent risk factors included suspected SOD, hilar stricture, more cannulation attempts, inadvertent PD cannulation, and PD contrast injections.
引用
收藏
页码:1903 / 1910
页数:8
相关论文
共 50 条
  • [1] Risk Factors for Post-ERCP Pancreatitis in High-Risk Patients Receiving Post-procedure Rectal Indomethacin
    Xiaoyu Kang
    Liyue Zheng
    Wei Zeng
    Shengye Yang
    Hao Sun
    Rongchun Zhang
    Xiangping Wang
    Biaoluo Wang
    Qin Tao
    Shaowei Yao
    Jie Chen
    Yanglin Pan
    Xuegang Guo
    Journal of Gastrointestinal Surgery, 2018, 22 : 1903 - 1910
  • [2] Indomethacin prevents post-ERCP pancreatitis in selected high-risk patients
    Mattia Bonzi
    Elisa Maria Fiorelli
    Internal and Emergency Medicine, 2012, 7 : 557 - 558
  • [3] Indomethacin prevents post-ERCP pancreatitis in selected high-risk patients
    Bonzi, Mattia
    Fiorelli, Elisa Maria
    INTERNAL AND EMERGENCY MEDICINE, 2012, 7 (06) : 557 - 558
  • [4] Pre-, intra-, and post-procedure risk factors for post-ERCP pancreatitis
    Petersen, BT
    Yacavone, R
    Pochron, N
    Harmsen, WS
    Zinsmeister, A
    Baron, T
    Gostout, C
    Wiersema, M
    GASTROINTESTINAL ENDOSCOPY, 2004, 59 (05) : AB115 - AB115
  • [5] Indomethacin Does Not Reduce Post-ERCP Pancreatitis in High-Risk Patients Receiving Pancreatic Stenting
    Bai, Bingqing
    Wang, Shaofei
    Du, Yemei
    Li, Mengwen
    Huang, Qiming
    Liu, Sisi
    Zhang, Chenyu
    Fang, Yuanyuan
    Chen, Xinwen
    Hong, Jianglong
    Li, Yang
    Xu, Zhangwei
    Liu, Xiaochang
    Hong, Rutao
    Bao, Junjun
    Mei, Qiao
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (09) : 3442 - 3449
  • [6] PREVENTION OF POST-ERCP PANCREATITIS IN HIGH-RISK PATIENTS
    Turovets, Mikhail
    Popov, Alexander
    Mandrikov, Viktor
    Vedenin, Yury
    Ekstrem, Andrej
    ARCHIV EUROMEDICA, 2021, 11 (02): : 72 - 77
  • [7] Does rectal indomethacin prevent post-ERCP pancreatitis in average-risk patients?
    He, Xing-kang
    Sun, Lei-min
    GASTROINTESTINAL ENDOSCOPY, 2017, 85 (03) : 687 - 687
  • [8] A Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine versus Rectal Indomethacin Alone for the Prevention of Post-ERCP Pancreatitis in High-Risk Patients
    Kamal, Ayesha
    Akshintala, Venkata
    Talukdar, Rupjyoti
    Goenka, Mahesh K.
    Kochhar, Rakesh
    Sinha, Saroj
    Goud, Rajesh
    Kumar, Vijay
    Elmunzer, B. Joseph
    Khashab, Mouen
    Kalloo, Anthony N.
    Reddy, Duvvur Nageshwar
    Singh, Vikesh K.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S429 - S429
  • [9] A Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine versus Rectal Indomethacin Alone for the Prevention of Post-ERCP Pancreatitis in High-Risk Patients
    Kamal, Ayesha
    Akshintala, Venkata
    Talukdar, Rupjyoti
    Goenka, Mahesh K.
    Kochhar, Rakesh
    Sinha, Saroj
    Goud, Rajesh
    Kumar, Vijay
    Elmunzer, B. Joseph
    Khashab, Mouen
    Kalloo, Anthony N.
    Reddy, Duvvur Nageshwar
    Singh, Vikesh K.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S429 - S430
  • [10] Risk factors for post-ERCP pancreatitis
    Kadayifci, A.
    ENDOSCOPY, 2008, 40 (01) : 81 - 81